|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| A randomised trial of lymphadenectomy and of adjuvant external beam radiotherapy in endometrial cancer |
| Source of record | UK Trials |
| ISRCTN | ISRCTN16571884 |
| Date ISRCTN assigned | 06/04/2000 |
| Local reference number(s) | UT01 |
| Public title | A randomised trial of lymphadenectomy and of adjuvant external beam radiotherapy in endometrial cancer |
| Scientific title | |
| Acronym | ASTEC |
| Disease/condition/study domain | Cancer |
| Study hypothesis | 1. To determine the benefit or otherwise of lymphadenectomy in patients with endometrial cancer (thought pre-operatively to be confined to the corpus). 2. To determine the benefit or otherwise of post-operative adjuvant radiotherapy in patients with endometrial cancer, high risk pathology and no macroscopic disease following surgery |
| Design/methodology | Randomised controlled trial |
| Research ethics review | Not provided at time of registration. |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | Surgical randomisation inclusion: 1. Histologically proven diagnosis of endometrial carcinoma 2. Disease thought pre-operatively to be confined to the corpus (CT or MRI scanning suggesting node enlargement is not an exclusion to randomisation and should not influence the decision to randomise) 3. Patient fit to undergo lymphadenectomy 4. Centre able to offer appropriate surgery 5. Patient fit to receive external beam radiotherapy 6. Written informed consent (for randomisation into both surgical and radiotherapy components). Radiotherapy randomisation inclusion: 1. Histologically proven diagnosis of endometrial carcinoma 2. Disease pre-operatively confined to the corpus 3. Macroscopically free of disease (positive para-aortic nodes should be viewed as indicative of further [unseen] macroscopic disease) 4. Fit to receive external beam radiotherapy 5. High risk pathology, assessed independently of nodal status, defined as one or more of the following: Grade 3 (poorly differentiated) or Invasion to the outer half of the myometrium or Serous papillary or clear cell type or Stage IIA 6. Written informed consent. |
| Participants - exclusion criteria | Not provided at time of registration |
| Patient information material | |
| Anticipated start date | 01/04/1998 |
| Anticipated end date | 01/01/2005 |
| Status of trial | Completed |
| Target number of participants | 2300 |
| Interventions | There are four groups: 1. The first group receives standard surgery alone. 2. The second group receives standard surgery plus lymphadenectomy 3. The third group receives standard surgery plus (external beam) radiotherapy 4. The fourth group receives standard surgery plus lymphadenectomy plus (external beam) radiotherapy. |
| Primary outcome measure(s) | Primary endpoint is survival. |
| Secondary outcome measure(s) | Secondary endpoints are recurrence-free survival and quality of life. |
| Trial website | http://www.ctu.mrc.ac.uk/studies/ASTEC.asp |
| Sources of funding | Medical Research Council (UK) |
| Sponsor name | Medical Research Council (UK) |
| Sponsor details | 20 Park Crescent London United Kingdom W1B 1AL |
| Sponsor telephone | +44 (0)20 7636 5422 |
| Sponsor fax | +44 (0)20 7436 6179 |
| Sponsor email | clinical.trial@headoffice.mrc.ac.uk |
| Sponsor website | http://www.mrc.ac.uk |
| Contact name | Ms Claire Amos |
| Contact details | MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN16571884 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | |
|
|
|
|